Plasma substitutes and perfusion solutions and dialytics or haemodialytics and drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (A61P7/08)

A   Human necessities(312083)
A61P7/08                     Plasma substitutes; perfusion solutions; dialytics or haemodialytics; drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears a61p0027040000)(80)
Energometabolic composition for preventive therapy of metabolic acidosis, ketosis, and iodine deficiency in cows // 2620557
FIELD: agriculture.SUBSTANCE: claimed energometabolic composition for preventive therapy contains beet molasses, succinic acid and citric acid, sodium chloride, iodinol in aqueous solution in the following ratio, wt %: succinic acid - 1,5, citric acid - 0,15, beet molasses - 50, sodium chloride - 2,5, iodinol - 5,0, water - the rest The claimed method involves the use of the claimed composition with the multiplicity of once in 5-7 days by watering animals at a dilution of the composition in water of 1:5-7 or mixing it with the fodder.EFFECT: group of inventions relates to the field of veterinary medicine and is intended for the prevention of metabolic acidosis, ketosis, and hypothyroidism in cows.2 cl, 4 tbl, 1 ex

Liposomal composition for application in peritoneal dialysis // 2609860
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to medicine, namely to a liposome composition for application in peritoneal dialysis for patients with from endogenous or exogenous intoxication, wherein the pH inside the liposomes is characterized by the pH in the peritoneal cavity and is preferably 1.5-4.0 or 9.0-10.0, and wherein the pH inside the liposomes results in formation of a charged toxin, incorporated into a liposome.EFFECT: invention provides detoxification by charged toxin capturing within liposomes.8 cl, 5 ex, 5 dwg

ethod of infusion support for caesarean section under spinal anaesthesia // 2600668
FIELD: medicine.SUBSTANCE: invention relates to medicine, in particular to anesthesiology, and can be used to stabilize hemodynamics at abdominal delivery under spinal anesthesia. To do this, immediately before spinal anesthesia perform jet infusion of colloidal drug Polyoxyfumarin at a speed of 40 ml/min for 5 minutes. After intrathecal injection of anesthetic intravenous drip infusion of drug at a speed of 12-18 ml/min is continued to the end of the operation.EFFECT: invention helps to prevent hypotension, can reduce the use of vasopressors, prevents hypoxia in newborns.1 cl, 9 tbl, 2 ex

Polymer system with size adsorption selectivity // 2590225
FIELD: chemistry.SUBSTANCE: invention relates to a polymer system with selectivity of adsorption and, in particular, to polymer systems with multiple pores, including transport pores and negative ion charge on their surface. Biocompatible and/or hemocompatible polymer system with selectivity of adsorption-size, including at least one polymer with multiple pores, wherein said polymer contains transport pores with diameter of 250-2,000 Å and effective pores with diameter from 100 to 250 Å, volume of transport pores of said polymer ranges from 1.8 to 78 % of capacity of pore space of said polymer, and effective pore volume varies from 22 to 98.2 % capacity of pore space, where capacity of pores is sum of effective pores and transport pores and where space of pores greater than 300 Å is equal to 2.0 % or less of total pore space.EFFECT: invention enables to obtain adsorbents for hemoperfusion procedures, having high selectivity of adsorption of proteins of small and average size, except large proteins.15 cl, 1 dwg, 3 tbl, 4 ex

Adsorbents for oral administration // 2583934
FIELD: medicine.SUBSTANCE: invention relates to use of activated carbon fibres as an adsorbent toxin level when administered orally. Invention relates to activated carbon fibre-containing adsorbent for oral administration for treating or preventing renal diseases or complications dialysis.EFFECT: treatment or prevention of renal diseases or complications of dialysis.7 cl, 4 dwg, 5 tbl, 18 ex

Artificial plasma extender // 2582219
FIELD: medicine.SUBSTANCE: invention relates to medicine, particularly to plasma substituting solutions, and can be used in transfusion in treatment of hypovolemic states of different aetiology. Disclosed plasma solution contains hydroxyethyl starch and sodium fumerate as an electrolyte in following ratio: hydroxyethyl starch 58-62 g/l, sodium fumerate 15-17 g/l, water for injections up to 1,000 ml and has an osmolarity value of 280-320 mosm/l.EFFECT: invention provides replacement of volume of circulating fluid and restoration of hemocirculation and blood rheological properties, and also provides a specific cardiotonic effect, that is sharply increases minute volume of blood circulation and stroke output in short period of time after beginning of treatment, which effectively improves cardiac activity and restores parameters of acid-base balance of body.1 cl, 2 tbl

Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods for thereof obtaining and application // 2570007
FIELD: chemistry.SUBSTANCE: invention relates to methods for obtaining lanthanum carbonate compounds and their application, namely to methods for obtaining lanthanum carbonate hydroxide and lanthanul dioxycarbonate and pharmaceutical composition, containing lanthanum dioxycarbonate. Method for obtaining lanthanum carbonate compound includes realisation of reaction of soluble lanthanum chloride salt with ammonium carbonate in solvent at reaction temperature from approximately 75 degrees Celsius to approximately 90 degrees Celsius, at pH from approximately 6.0 to 7.5, and precipitation of reaction product, with reaction product representing lanthanum carbonate hydroxide, which contains approximately 0.5 wt % or less of sodium. With additional burning of reaction product at temperature from approximately 400 to approximately 700 degrees Celsius for two hours lanthanum dioxycarbonate, containing one or more polymorphic forms of formulae La2O2CO3 and La2CO5 and containing approximately 0.75 wt % or less of sodium, is obtained.EFFECT: invention provides obtaining lanthanum carbonate compounds, possessing improved properties.21 cl, 23 dwg, 20 tbl, 8 ex
Acid dialysis concentrate // 2568846
FIELD: medicine.SUBSTANCE: invention relates to medicine and describes precursor of acid dialysis concentrate, which consists of two separately prepared partial concentrates, with two separately prepared partial concentrates being prepared from component parts of acid dialysis concentrate, where only first partial concentrate contains glucose, while second partial concentrate does not contain glucose, and first partial concentrate together with glucose contains water, acidifier and KCl and/or MgCl, and/or CaCl2, and quantities of salts are selected in such a way that they are completely soluble in saturated glucose solution at temperature approximately 5°C, and component parts of glucose remain in insoluble condition, so that first partial concentrate is in condition of suspension, in addition, first partial concentrate is set to pH value from 2.5 to 3.2, preferably 3.0, and second partial concentrate contains sodium chloride, and/or potassium chloride, and/or calcium chloride, and/or magnesium chloride or respective hydrates, water and acidifier, and is condition of suspension, too, in which sodium chloride parts remain in insoluble condition, and other component parts are dissolved.EFFECT: invention ensures glucose stability and reduction of occupied area, first of all at storage.7 cl, 4 tbl
Solution for peritoneal dialysis // 2567043
FIELD: pharmacology.SUBSTANCE: intracorporeal detoxification preferentially conducted in a clinical setting involves using a solution containing albumin, Fraxiparine, dialysis fluid. The solution additionally contains papaverine, platyphyllin and heparine in the following proportions, wt %: albumin - 3-5%, Fraxiparine - 0.025-0.075%, papaverine - 0.3-0.6%, platyphyllin - 0.015-0.03%, heparin - 0.025-0.05%, dialysis fluid - the rest.EFFECT: more effective dialysis process, reduced length of stay in hospital.5 ex

ethod for preparing sterile nanoemulsion of perfluororganic compounds // 2557933
FIELD: medicine.SUBSTANCE: invention represents a method for preparing a sterile nanoemulsion of perfluororganic compounds (PFOC) involving: adding a PFOC mixture to an aqueous solution of a stabilising agent; homogenising the PFOC mixture with the aqueous solution of the stabilising agent to produce a PFOC pre-emulsion; mixing the PFOC pre-emulsion with a salt-water solution to produce the PFOC nanoemulsion; keeping the PFOC nanoemulsion at a temperature from 2 to 10°C for at least 18 hours. The method can be also implemented as follows: pre-filling a circulation loop of a PFOC nanoemulsion generating plant with the aqueous solution of the stabilising agent; adding the PFOC mixture to the aqueous solution of the stabilising agent; homogenising the PFOC mixture with the aqueous solution of the stabilising agent to produce the PFOC pre-emulsion; mixing the PFOC pre-emulsion with the salt-water solution to produce the PFOC nanoemulsion.EFFECT: higher stability of the PFOC emulsion and prolonging the storage life.30 cl, 7 ex, 5 tbl, 1 dwg
ethod of treating preeclampsia of moderate severity in women with alimentary obesity // 2549668
FIELD: medicine.SUBSTANCE: for patient with alimentary obesity preliminarily determined are: clearance of osmotically free water (CFW) and colloid oncotic pressure (COP). If CFW level is lower than -0.45 ml/min and COP is lower than 18 mm Hg, therapy starts from intravenous introduction of 6% HES "Voluven" in dose 6.5 ml/kg/day at rate 350 ml/h. Immediately after the end of infusion introduction with syringe doser of 25% solution of magnesium sulphate in dose 0.75 ml/kg/day at rate 2.8 ml/h. For patient without obesity, if CFW level is lower than -0.6 ml/min and COP is lower than 21 mm Hg, therapy is started from intravenous introduction of 6% HES "Voluven" in dose 5.5 ml/kg/day at rate 300 ml/h. 25% solution of magnesium sulphate in dose 0.9 ml/kg/day at rate 2.4 ml/h is also introduced by means of syringe doser. Treatment is carried out during a day.EFFECT: carrying out adequate therapy in said category of patients due to selection of mode of introduction of preparations, conditioning fast recovery of kidney function.2 cl, 2 ex

Balanced infusion solution // 2549448
FIELD: medicine.SUBSTANCE: invention represents a balanced infusion solution containing sodium, potassium and magnesium chlorides, a solvent and sodium L-arginine succinate of formula: Na+[NH=C(NH2)NH(CH2)3CH(NH2)COOH]+[OOC(CH2)2COO]2-. The ingredients in the solution are found in certain proportions, wt %.EFFECT: invention provides enhanced detoxification activity, low toxicity and wide range of clinical applications.11 tbl, 6 ex
ethod for determining infusion therapy extent in alcoholic encephalopathy // 2547245
FIELD: medicine.SUBSTANCE: body weight, physiological requirements and degree of disease severity are determined. That is followed by calculating an infusion therapy extent by formula: V=Ce×BW+PR+300 ml 5% glucose, wherein V is the infusion therapy extent, ml; Ce is an encephalopathy coefficient: 0.02 in prodromal period, 0.03 in manifested psychosis, 0.04 in chronic alcoholic encephalopathy; BW is patient's body weight, gram; PR are the physiological requirements for one day, ml.EFFECT: method provides the effective infusion therapy in the given category of patients by the accurate determination of the therapy extent caused by taking into account the stages of alcoholic encephalopathy development.3 ex
Pharmaceutical substance and method of obtaining thereof // 2546286
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to medicine and consists in a pharmaceutical substance, representing an instantly soluble in water powder of a crystalline chemical compound of dextrose with sodium chloride - (C6H12O6)2·NaCl·H2O, which has a specific rotation of a polarised light plane initial at 113°, equilibrium at 52.9°, constant of the mutarotation rate of 6.7·10-3 and moisture content of not more than 4.3%. The invention also relates to a method of obtaining the pharmaceutical substance.EFFECT: pharmaceutical substance has stable quality, is easily packaged, it is possible to prepare a solution for injections from it in a fast and easy way, its storage and transportation are considerably more simple.2 cl, 1 ex

ethod for prevention of spinal headache in bone marrow donors in spinal and combined spinal epidural anaesthesia // 2543351
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to anaesthetics, and can be used for the prevention of spinal headache during spinal or combined spinal epidural anaesthesia in bone marrow exfusion. That is ensured by an intravenous infusion of 6% hydroxyethylstarch 500 ml 30 minutes before the subarachnoid puncture and the spinal and combined spinal epidural puncture or for the first 30 minutes of the anaesthesia.EFFECT: invention provides preventing postoperative spinal headache in this group of patients.1 dwg, 1 tbl, 4 ex
ethod for prevention of diffuse intra- and postoperative blood loss in surgery of abdominal aorta // 2540923
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to cardiovascular surgery, and concerns preventing a diffuse intra- and postoperative blood loss in surgery of abdominal aorta. To this effect, performing the aortoiliac operations is combined with measuring preoperative antithrombin III; if the measured value is less than 87±3%, a thromboelastography is performed from the moment of an anaesthetic support started with determining a coagulation index. If the coagulation index is less than 2.89±0.25 as early as at the start of the stage of approaching the abdominal aorta, before any surgically significant blood loss, fresh-frozen plasma of the identical group in a min. amount of 600 ml is administered into the patient. If the following dynamic control shows a decrease of the coagulation index below 1.10±0.28, at least 600 ml of fresh-frozen plasma is additionally administered, providing thereby the coagulation index by the end of the operation not less than 0.52±0.27.EFFECT: method provides effective prevention of intra- and postoperative blood loss by prevention of intraoperative homeostatic disorders.

Concentrated acidic component, kit for producing it, concentrated solution of acidic component for producing hemodialysis solution and method for producing it // 2536994
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a concentrated acidic component for producing a hemodialysis solution. The acidic component contains the following ingredients in an amount of producing 1 litre of the solution in water purified for hemodialysis: 204.7-215.0 g of sodium chloride NaCl, 6.2-9.0 g of calcium chloride CaCl2*2H2O, 3.56-7.12 g of magnesium chloride MgCl2*6H2O, 5.22-10.44 g of potassium chloride KCl, 0.021-6.28 g of acetic acid and 0.02-6.2 g of succinic acid. Also, the invention refers to the hemodialysis solution containing the above concentrated acidic component, water purified for hemodialysis, and bicarbonate component. The invention also refers to a method for producing the hemodialysis solution with the method involving supplying the concentrated acidic component into a hemodialysis apparatus, diluting with water purified for hemodialysis, and mixing with bicarbonate component. What is also declared is a kit for producing the concentrated acidic component containing sodium chloride, calcium chloride, magnesium chloride, potassium chloride, succinic acid in the form of dry agents and acetic acid in the form of a liquid agent.EFFECT: invention provides higher effectiveness by a biochemical compatibility with blood plasma of the hemodialysis solution.36 cl, 18 tbl, 16 ex

Composition, containing crystallisation-inhibiting substances // 2535094
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to a composition, adapted for intravenous introduction, intended for the treatment or prevention of pathological processes of crystallisation or calcification in a person, subjected to dialysis. The composition contains inositol phosphate and/or its pharmaceutically acceptable salt, with a dose of inositol phosphate and/or its salt constituting from 1 nmol/kg to 0.1 mil/kg. The invention also relates to a combined method of treatment, including the intravenous introduction of the said composition of the dialysis liquid simultaneously.EFFECT: method is intended for the treatment or prevention of pathological processes, associated with an impairment of the regulation of physiologically adequate levels of inositol phosphate in blood plasma of the person, subjected to dialysis.10 cl, 4 dwg, 1 tbl, 9 ex
Physiolite infusion solution // 2533257
FIELD: medicine.SUBSTANCE: what is declared is an infusion solution for filling the deficiency and meeting the physiological needs for water and basic electrolytes, which contains the following ingredients: sodium (Na+) - 27.72-28.28 mmole/l; fumarate(H2C4O4 2-) - 13.86-14.14 mmole/l; potassium (K+) - 18.61-18.99 mmole/l; calcium (Ca2+) - 3.56-3.64 mmole/l; magnesium (Mg2+) - 2.18-2.22 mmole/l; chlorine (Cl-) - 30.0-30.6 mmole/l; glucose (C6H12O6) - 189.1-192.9 mmole/l, water for injections.EFFECT: solution contains the basic electrolyte concentration balanced for meeting the physiological needs; it is safe for the clinical application and can be used in diseases of various aetiology for patients of any age.1 tbl, 2 ex
ethod for intraoperative and early postoperative infusion therapy // 2523555
FIELD: medicine.SUBSTANCE: invention refers to medicine and aims at intraoperative and early postoperative infusion therapy. A method involves administering a crystalloid balanced solution of sterofundin iso and a balanced colloidal solution of tetraspan. In the intraoperative period, sterofundin is administered with tetraspan in the volume ratio 3:1. In the early postoperative period, for the first day, sterofundin and tetraspan are administered in the volume ratio 6:1.EFFECT: method is simple, safe, enables effectively correcting aqueous electrolyte disorders, stabilising systemic hemodynamic parameters, causing no negative effect on haemostasis and electrolyte composition of the blood serum.1 ex, 1 tbl
Solution for bicarbonate hemodialisys // 2521361
FIELD: chemistry.SUBSTANCE: invention relates to a concentrated acid component for bicarbonate hemodialysis. The acid component includes sodium (Na+) in an amount of 2450.0-4550.0 mEq/l, chlorine (Cl-) in an amount of 2453.5-4553.5 mEq/l, hydrogen H+ (hydrochloric acid), succinate and citrate, each in an amount of 3.5-98.0 mEq/l. The invention also relates to a diluted acid component for bicarbonate hemodialysis, which includes sodium chloride 70.0-130.0 mEq/l, hydrochloric acid 0.1-2.8 mEq/l, succinic acid 0.1-2.8 mEq/l, and citric acid 0.1-2.8 mEq/l. The invention also relates to a concentrate for preparation of the acid component, which contains hydrochloric acid in a liquid form, and all other components in a dry form, as well as to a method of obtaining the acid component, which includes dissolution of dry chemical reagents from the said concentrate in water and addition of liquid reagents.EFFECT: invention ensures obtaining a solution for dialysis, applied in case of acute and chronic renal failure.14 cl, 1 tbl, 3 ex
ethod for determining suitability of preserved packed red cells for transfusion // 2518344
FIELD: medicine.SUBSTANCE: before transfusion, a preserved blood sample of 2 ml is mixed with an ozonised solution of 0.9% sodium chloride with the ozone concentration of 2 mg/l in the equivalent volume. The 15-minute exposition is followed by evaluating the 2,3 diphosphoglycerate concentration in the prepared packed red cell suspension. The 2,3 diphosphoglycerate concentration in the packed red cell suspension more than 6 mcmole/l testifies to the high effectiveness of planned hemotransfusion.EFFECT: using the invention provides higher accuracy of determining the suitability of the preserved packed red cells for transfusion that ensures higher clinical effectiveness in the severe patients by fast and stable correction of oxygen delivery and consumption preferentially by functionally adequate red cells.2 ex
Perfluorinated blood substitute - gas transport donor blood substitute: formulation and treatment // 2518313
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry and represents a formulation of a perfluorinated blood substitute emulsion for biomedical applications, containing: perfluorinated hydrocarbons, emulsifying agents and an electrolyte solution differing by the fact that it contains a binary mixture of two perfluorinated hydrocarbons in ratio 1.55 to 1.99 in the concentration of 5 - 1000 g/l, with an average particle size of a perfluororganic compound of 25 - 250 nm; a binary mixture of the emulsifying agents in ratio 1.55 to 1.99 that are non-ionic block copolymers of ethylene oxide and propylene oxide - proxanoles: proxanole-268/proxanole-168; proxanole-268 in the concentration of 1 - 200 g/l with the molecular weight of 7 - 14 thousand Da; proxanole-168 in the concentration of 1 - 200 g/l with the molecular weight of 5 - 7 thousand Da; the electrolyte solution: NaH2PO4 - 0.18-0.25 g/l; NaCl - 5.5-6.5 g/l; and/or KCl - 0.37-0.41 g/l; and/or MgCl2 - 0.17-0.21 g/l; and/or NaHCO3 - 0.35-0.7 g/l; and/or glucose - 1.5-2.5 g/l.EFFECT: invention ensures formulating the perfluorinated blood substitute with better aggregation and sedimentation stability and lower toxicity.2 cl, 9 ex

ethod of predicting massive intraoperative blood loss in operations on account of non-organ retroperitoneal tumours // 2489087
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to surgery, anesthesiology and intensive therapy, oncology, and can be applied in operations on account of non-organ retroperitoneal tumours. For this purpose prognostic criteria are determined on the basis of clinical and anamnestic parameters: Long stands for longitudinal dimension of tumour, in cm; Transv stands for transverse dimension of tumour, in cm; Rad stands for radical character of operation: 1 point means presence of radical intervention; 0 points means absence, palliative surgery, exploratory laparotomy; AddRes means carrying out additional resection of organs: 1 point means presence of organ resection; 0 points means operation only on tumour ablation; PorS stands for surgery on main vessels: 1 point stands for vascular plasty of arteries, resection of fragments of inferior vena cava, aorta; DifG stands for diffusion growth of tumour without capsulation: 1 point means presence; 0 points means absence. After that, coefficient of regression Z is calculated: Z=-0.581+0.038×Long+0.02×Transv+0.073×Rad+0.166×AddRes+0.133×PorS+0.102×DifG and substituted into formula: P1=11+e−(1,2−4,18×Z) where e is base of natural logarithm with value e=2.72. If P1 constitutes from 0.87 to 0.26, massive intraoperative blood loss, requiring increased dose of colloids, but not more than 40 ml/kg/day in carrying out infusion therapy, is predicted.EFFECT: method makes it possible to select optimal tactics of compensation of intravascular volume of colloids in operations in said category of patients due to more accurate calculation of blood loss volume.1 ex
Gizatullin's method of determining optimal volume of infusion therapy for injured in frostbites in state of narcotic intoxication after application of dezomorphin // 2487664
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to intensive therapy and narcology, and can be used in treatment of patients with frostbites, who are in the state of narcotic intoxication of different severity. For this purpose determined are: area of affection, degree of frostbite, degree of narcotic intoxication, physiological needs of organism and pathological loss during a day. After that, volume of infusion therapy is calculated by formula: V=(Cfs×S)+(Cn×MVDIT)+PN+PL, where: V is volume of infusion therapy, in ml; Cfs is coefficient of frostbite severity: 1.0 in case of I and II degree frostbites; 2.0 in case of III-IV severity degree frostbite; S is area of affected surface, in cm2; Cn is coefficient of narcotic intoxication severity: 1.0 - in case of changed reactivity to narcotic substance; 1.5 - in case of psychic dependence (obsessive attraction); 2.0 - in case of physical dependence (compulsive attraction); 2.5 - in case of abstinence syndrome; MVDIT is minimal volume of disinfection infusion therapy in case of application of dezomorphin, equal to 1250 ml of infusion solutions per day; PN stands for physiological needs of organism during a day; PL stands for pathological loss during a day, constituting 500 ml in case of I and II degree of frostbites and 1000 ml in case of III and IV degree of frostbites.EFFECT: method ensures adequate and differentiated performance of infusion therapy in said category of patients taking into account degree of narcotic intoxication, which contributes to prevention of "mutual aggravation", minimisation of disorders of hemostasis, microcirculation, as well as prevention of encephalopathy of complex genesis, including carrying out necrotomy and fasciotomy.3 ex
ethod of determining volume of infusion therapy in case of frostbites // 2486865
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to surgery and intensive therapy, and can be used in treatment of patients with frostbites. For this purpose degree of frost bite severity, area of affection, physiological needs of organism and pathological loss during a day are determined. After that, volume of infusion therapy is calculated by formula: V-C×S+PN+PL, where: V is volume of infusion therapy, in ml; C is coefficient of frost bite severity: 1.0 in case of I and II degree frostbites; 2.0 in case of III-IV degree frostbites; S is the area of affected surface, in cm2; PN stands for physiological needs of organism during a day, in ml; PL stands for pathological loss during a day, in ml.EFFECT: method ensures elimination of hemostasis and microcirculation disorders in pre-reactive period, as well as in early and late reactive periods due to carrying out adequate infusion therapy with optimal volume of solutions.3 ex
Pm zinatullin's method of determining optimal volume of infusion therapy for injured in frostbites in state of alcoholic intoxication // 2486864
FIELD: medicine.SUBSTANCE: invention relates to narcology, and can be used in treatment of patients with frost bites, who are in the state of alcoholic intoxication of different severity. For this purpose determined are: degree of frostbite, area of affection, degree of alcoholic intoxication, physiological needs of organism and pathological loss during a day. After that, volume of infusion therapy is calculated by formula: V=(CfsxS)+(CfxSVIT)+PN+PL, where: V is volume of infusion therapy, in ml; Cfs is coefficient of frost bite severity: 1.0 in case of I and II degree frost bites; 2.0 in case of III-IV severity degree frost bite; S is area of affected surface, in cm2; Ca is coefficient of alcoholic intoxication severity: 0.5 in case of mild degree, 0.75 in case of medium severity; 1.0 in case of severe degree; 1.5 - in case of alcoholic coma; SVIT is standardised volume of infusion therapy, in case of alcoholic intoxication equal 2500 ml per day: PN stands for physiological needs of organism for a day, in ml; PL stands for pathological loss within a day, in case of I and II degree frost bites constituting 500 ml; in case of III and IV degree frost bites constituting 1000 ml.EFFECT: method ensures adequate and differentiated carrying out infusion therapy in said category of patients, taking into account degree of alcoholic intoxication, which contributes to prevention of "mutual aggravation" syndrome, minimisation of hemostasis and microcirculation, as well as prevention of encephalopathy of complex genesis, alcoholic psychosis, including cases after carrying out necrotomy and fasciotomy.3 ex
ethod of treating hemorrhagic shock of i, ii and iii degree of severity // 2482840
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to resuscitation and intensive therapy and can be used in treatment of hemorrhagic shock of I, II and II degree of severity. Method of hemorrhagic shock treatment. For this purpose, assessment of degree of hemorrhagic shock severity is carried out, and in case of hemorrhagic shock of 1 degree of severity in the programme of infusion therapy included are: crystalloid solution of isotopic sterofundin in dose 3000 ml per day and 4% colloidal solution of modified gelatin in volume 1000 ml per day, in case of hemorrhagic shock of II degree of severity - 1200 and 2500 ml respectively, in case of hemorrhagic shock of III degree of severity - 1200 and 3500 ml respectively.EFFECT: method makes it possible to improve results of treating patients with hemorrhagic shock at pre-hospital and hospital stages due to reduction of risk of electrolyte and acid-alkaline disorders.1 ex
ethod for prevention of severe complications accompanying surgical management of massive and submassive blood loss with continuous haemorrhages // 2475234
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely resuscitation and may be used for prevention of severe complications in surgical management of massive and submassive blood loss with continuous haemorrhages. That is ensured by the intraoperative intravenous drop-by-drop introduction of Perftoran 2-4 ml/kg following mechanical arrest of the continuous haemorrhages. With underlying restorable blood volume, higher body oxygenation with eliminated nitrogen oxide inhalation. Rheamberyn is introduced in an average therapeutic dose at the end of the operation and on the first three postoperative days.EFFECT: invention provides higher effectiveness of infusion-transfusion management, improved clinical course of the operative and postoperative period, reduced percentage of complications and mortality.2 ex
ethod for correction of unfavourable changed of water and electrolyte metabolism in divers // 2472521
FIELD: medicine.SUBSTANCE: invention refers to medicine. What is prescribed is taking a beverage made of soluble granulated magnolia-vine extract. The beverage 250 ml is taken before a dip for 20 days three times a day.EFFECT: use of the declared method enables unfavourable changes of water and electrolyte metabolism in divers.1 ex
ethod for prevention of compressed-air disease in divers // 2472520
FIELD: medicine.SUBSTANCE: invention refers to medicine. What is prescribed is a beverage made of soluble granulated magnolia-vine extract. The beverage 250 ml is taken before a dip (compression in a vacuum chamber) for 20 days three times a day.EFFECT: method is high-effective for prevention of compressed-air disease in divers.1 ex
Preparations improving survival rate in wound shock // 2471489
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine and pharmacology and represents the use of water-soluble hybrid macromolecular compounds: O-(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionyl)-(1→6)-α-D-glucan, polyethylene glycol bis-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-propionate as agents improving survival rate in wound shock.EFFECT: invention provides the extended range of products applied in therapy for wound shock.4 ex, 1 tbl
ethod of determining volume of deintoxication-infusion therapy for patients in state of drug intoxication with use of desomorphine // 2463956
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to combuistology, resuscitation and intensive care, narcology and can be used in patients in state of drug intoxication with use of desomorphine. For this purpose determined are patient's body weight, degree of drug intoxication expression and physiological needs of organism during a day. After that volume of deintoxication-infusion therapy is calculated by formula: V= Cdix(CsxBW)+ PN, where V is volume of infusion therapy, in ml; Cdi - coefficient of drug intoxication expression: 1.0 in case of changed reactivity to drug substance; 1.5 - in case of presence of psychic dependence (obsessive attraction); 2.0 - in case of presence of physical dependence (compulsive attraction); 2.5 - in case of abstinence syndrome; Cs is coefficient of somatic aggravation with use of desomorphine, equal 0.2; BW is patient's body weight in grams; PN is physical needs of organism during a day, in ml.EFFECT: method makes it possible to ensure adequate infusion therapy in patients with different degree of expression of drug intoxication with desomorphine.1 ex
ethod of intestinal peristalsis stimulation // 2462241
FIELD: medicine.SUBSTANCE: invention relates to medicine, and is intended for stimulation of intestinal peristalsis in early post-operation period in patients with cancer of esophagus and cardial part of stomach. Plasma-substituting solution "Mafusol" is introduced enterally. "Mafusol" is additionally introduced parenterally in quantity 800-1200 ml per day.EFFECT: method makes it possible to restore intestinal peristalsis on first-second day after operation.4 ex
Plasma-substitute preparation with rheological and hemodynamic properties and agent for treating // 2461383
FIELD: medicine, pharmaceutics.SUBSTANCE: declared invention refers to chemical-pharmaceutical industry, and concerns a plasma-substitute compound with the rheological and hemodynamic properties on the basis of a block copolymer of ethylene oxide and propylene oxide, and hydroxyethylstarch, and using it in medicine and cosmetology.EFFECT: preparing the plasma-substitute compound with the improved rheological and hemodynamic properties of mixed two active ingredients: the surfactant proxanol - the block copolymer of ethylene oxide and propylene oxide of molecular weight 1 to 20 kDa and the hemodynamic agent hydroxyethylstarch of molecular weight 40 to 200 kDa in the ratio of 1/1 to 10/10 respectively with an acceptable electrolyte solution.10 cl, 8 ex
ethod of local treatment of folliculitis and furuncles // 2446784
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to purulent surgery, and may be used in treating patients with folliculitis and furuncles. For this purpose, at first forceps are used to remove an inflammation cone cover. A syringe is used to aspirate the purulent-necrotic mass. Before bandaging, the inflammation region is treated with the preparations Polcortolon or Oxycort.EFFECT: method provides a cosmetic effect ensured by prevented formation of a hard hypertrophic scar due to elimination of punctures and incisions.2 ex
ethod for intensive care of multiple-organ-failure syndrome // 2444379
FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly anesthesiology and intensive care, and can be used for treating multiple-organ-failure syndrome in the patients who underwent cardiac surgeries. That is ensured by evaluation of the risk factors of developing multiple-organ-failure syndrome. Their absence enables standard intensive care. If within 12 hours after the cardiac surgery there are observed acute reduced cardiac output and reduced ejection fraction with the combined introduction of adrenaline and dobutamine appeared to be ineffective, differentiated interventional therapy of multiple-organ-failure syndrome is performed with using a calcium-sensitising agent taken among the cardiac support. The presence of haemodynamic criteria of acute lung injury combined with systemic inflammation response, prolonged renal replacement therapy in continuous veno-venous hemofiltration is performed. It is combined with a simultaneous complex of respiratory kinesiological rehabilitation with differentiated selection of a respiratory support method. On the forth day of artificial pulmonary ventilation, puncture-dilatation tracheostomy is performed.EFFECT: method provides predicting a risk of developing multiple-organ-failure syndrome in a given category of patients at the early stage following the surgery.2 ex
ethod of treating rhesus-sensitisation and prevention of hemolytic disease of fetus with application of plasmapheresis and immunoglobulin therapy // 2438717
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to obstetrics and gynecology, and can be used in treatment of rhesus sensitisation and prevention of hemolytic disease of fetus. For this purpose titre of rhesus-antibodies is determined and if titre of rhesus-antibodies is higher than 1:32 and high titre of subclasses IgG1 and IgG3 carried out is course of therapeutic plasmapheresis, which includes from 3 to 5 sessions with removal of 10-30% of circulating plasma volume. Plasma compensation is performed with hydroxyethylated starch with ratio to removed plasma 1.2-1.5:1. Interval between sessions of therapeutic plasmapheresis constitutes 1-2 days. After finishing course of therapeutic plasmapheresis, intravenous immunoglobulin therapy is performed in dose 5.0 g with interval between immunoglobulin transfusions 1-2 days. If titre of rhesus-antibodies higher than 1:32 and high titre of subclasses IgG1 and IgG3 remains, courses of therapeutic plasmapheresis and immunoglobulin therapy are repeated throughout pregnancy.EFFECT: method ensures prevention of development of severe forms of hemolytic disease of fetus and makes it possible to prolong pregnancy to terms of obtaining viable fetus due to stable reduction of titre of rhesus-antibodies and titre of IgG1 and IgG3 subclasses, as well as minimisation of probability of rebound-effect development as a result of combined application of therapeutic plasmapheresis and immunoglobulin therapy.3 ex
ethod for making hemodialysis solution for bicarbonate hemodialysis // 2438663
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, and concerns a method for making a hemodialysis solution used in extracorporal blood purification for treating patients with acute and chronic renal insufficiency. The hemodialysis solution contains the following components, mmol/l: Sodium chloride NaCl 137.3-140.3; Calcium chloride CaCl2·2H2O 1.2-1.75; Magnesium chloride MgCl2·6H2O 0.5-1.0; Potassium chloride KCl 0.3-4.0; Glucose, g/l 1.0-5.0; Hydrochloric acid 0.1-2.9; Amber acid C4H6O4 0.1-2.9; Sodium bicarbonate 32.0.EFFECT: invention aims at producing a physiologic composition of an acid component with no acetic acid added, providing minimum complications in the form of acidosis, and haemodynamic stability in patients of a risk group and a cardiac intensive profile.4 ex

ethod of relieving pain shock severity in burning injury // 2432146
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to combustiology, and can be used in treating the patients with pain shock developed owing to a burning injury. For this purpose, a bath is filled with water of temperature 30°C and less with a burn solution added. Said solution contains the following ingredients taken in certain proportions, wt %: nettle - 5-25, bottle brush - 5-15, celandine - 10-15, sophora - 10-20, calendula - 10-20, hips - 5-15, common plantain - 10, echinacea - 10-25, sea-buckthorn - 5-10, chamomile - 5-10, a colloidal silver solution - 1, a sea salt solution - 2-3. Thereafter, water temperature is gradually decreased until observing an effect of stable pain relief in the patient.EFFECT: method provides stable pain relief for a short period of time that provides higher effectiveness of the intensive therapy carried out in the given category of patients.1 dwg, 4 ex

Pharmaceutical composition of hydroxyethyl starch in hypertonic saline used as plasma volume replacement solution in low-volume resuscitation // 2431488
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to chemical-pharmaceutical industry. A preparation has the minimum side effects and allows fast and reliable volemic and haemodynamic effects in low-volume infusion, as a rule, 4 ml/kg of body weight. What is offered is a combined hypertonic colloidal solution of hydroxyethyl starch differing by the fact that there is used 6.0 % hydroxyethyl starch of molecular weight 130 kDa and molar substitution 0.4, and 7.2 % hypertonic isotonic saline.EFFECT: preparation allows filling total blood volume (TBV) in a surgical patent in a small pre-admission period of time.1 tbl, 1 dwg
Peritoneal dialysate // 2429822
FIELD: medicine.SUBSTANCE: peritoneal dialysate contains 0.05 to 3.5 wt/vol % of taurine and 0.1 to 6.5 wt/vol % of trehalose as osmotic agents and exhibiting a pH value regulated between 6.5 to 7.5.EFFECT: invention provides safe and high-stable peritoneal dialysate which does not induce peritoneal membrane disorders, peritoneal sclerosis accompanying recurrent peritoneal-dialysis therapy, can protect residual renal functions in chronic renal insufficiency and delayed progression of renal injury for a long period of time, enabled peritoneal-dialysis therapy in a diabetic patient.33 cl, 3 tbl
Anti-inflammatory and anti-allergic medication and based on it pharmaceutical composition // 2426540
FIELD: medicine, pharmaceutics.SUBSTANCE: claimed is application of arbidol (1-methyl-2-phenylthiomethyl-3-carb-ethoxy-4-dimethilamino-methyl-5-oxy-6-bromidole of monohydrate hydrochloride) or its pharmaceutically acceptable salts and/or hydrates for manufacturing topic medications, intended for treatment of inflammatory and allergic skin diseases and topic pharmaceutical composition on its basis.EFFECT: demonstrated is therapeutic action - reduction of skin affection on standard models of allergic and contact dermatitis with minimal number of side effects.5 cl, 2 tbl, 3 ex

Application of beta-hydroxybutyrate or its pharmaceutically acceptable salts for preparation of medication which possesses cytoprotective activity, including neuroprotective, cardioprotective, anti-ischemic, anti-hypoxic, anti-stress, actoprotective and adaptogenic activity, medication and method of prevention, relief and treatment by means of said medication // 2426535
FIELD: medicine, pharmaceutics.SUBSTANCE: claimed is application of beta-hydroxybutyrate or its salts in combination with other active substance or combination of active substances, selected from group, given in the invention formula, for preparation of medication, which possesses cytoprotective activity, including neuroprotective, cardioprotective, anti-ischemic, antihypoxic, antistress and adaptogenic activities, medication and method of prevention, relief and treatment by means of said medication. Demonstrated is synergic of medication components as cytoprotector in urgent states as it possesses complex impact on key links of pathogenesis of said diseases.EFFECT: elaboration of medication which possesses cytoprotective activity.24 cl, 3 tbl, 5 ex
Infusion solution for total blood volume replacement, hydro-electrolytic rebalancing and hematopoiesis process normalisation // 2423987
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to an infusion solution for total blood volume replacement, hydro-electrolytic rebalancing, trace recovery, and hematopoiesis process normalisation. The declared solution contains sodium, potassium, calcium, magnesium, chloride and acetate ions with water, and in addition it contains cobalt, zinc and manganese ions in the following proportions, mmole: Na+ -140; K+ - 4; Ca++ - 2,5; Mg++ - 1; Co++ - 0.0006; Zn++ - 0.022; Mn++ - 0.004; CI- - 111; CH3COO- - 40; and water for injections up to 1 l.EFFECT: solution is balanced in relation to an ionic composition of human blood plasma and effects on erythropoiesis stimulation.8 tbl, 7 ex
ethod of obtaining dialysing solution // 2418596
FIELD: medicine, pharmaceutics.SUBSTANCE: acidic concentrated solution is supplied into apparatus "Artificial kidney", which in automated mode performs its dissolution in ratio, specified by apparatus programme, and mixing with bicarbonate component. Obtained dialysing solution contains the following components, in mmol/l: sodium chloride NaCl 137.3-140.3, calcium chloride CaCl2·2H2O 1.2-1.75, magnesium chloride MgCl2·6H2O 0.5-1.0, potassium chloride KCl 0.3-4.0, sodium diacetate 0-6.0, succinic acid 0.44 or 0.88 or 1.0, glucose, g/l 0-5.0, sodium bicarbonate NaHCO3 32.0.EFFECT: elaboration of efficient method of obtaining hemodialysing solution for bicarbonate hemodialysis for treatment of patients with acute and chronic renal failure6 ex
edication for treating blood loss ("spaskrov") // 2416413
FIELD: medicine.SUBSTANCE: claimed is medication for treatment of blood loss, consisting of complex representing combination of insulin 14 U, glucose solution 10% - 400 ml, sodium adenosine triphosphate 1% - 1 ml, panangin 10 ml, strophanthin acetate 0.05% - 0.25 ml, ascorbic acid 5% - 2 ml, riboxin 10ml, analgin 25% - 1 ml, polyglucinum 6% -400 ml.EFFECT: medication in express-mode simultaneously produces rehabilitating action on all factors of blood loss etiopathogenesis, including elimination of acidosis, stress and pain syndrome.1 ex

Perfluorocarbonic gas-carrying emulsion for medico-biological aims: method of obtaining blood-substituting composition // 2415664
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to chemical-pharmaceutical industry and deals with elaboration of method of obtaining blood-substituting composition on two high pressure desintegrators from the mixture of two perfluorocarbons, quickly excreted (C8-C10) and(or) slowly excreted (C11-C12), is emulsified with proxalon-268 from 0.2% to 20% with molecular weight 6-12 thousand Da, with further addition of acceptable electrolyte solution, with formation of fine dispersion emulsion with the average particle size 30-120 nm. Method is realised by homogenisation of obtained mixture on two high pressure homogenisers with two or four extrusion devices of homogenisers.EFFECT: method makes it possible to obtain highly stable perfluorocarbonic emulsions, which possess lower reactogenicity.12 cl, 6 ex, 1 tbl, 1 dwg
ethod of detoxification in peritonitis patients // 2411046
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely, to efferent methods in surgery, and can be used in treating peritonitis patients. That is ensured by prolonged venovenous hemofiltration. In 2 hours after the procedure started, through a catheter inserted in a subclavian vein or a abdominal aorta with using a peristaltic pump for 15 minutes 250 ml of HyperHAES solution is introduced.EFFECT: method allows higher effectiveness of detoxification ensured by an effect of endotoxin redistribution in a vascular bed from an interstitial space owing to introducing the hydroxyethyl starch solution followed by endotoxin elimination from the vascular bed by hemofiltration.1 tbl, 1 ex
ethod of applying autoplasmodonorship and acute normovolemic hemodilution in case of abdominal labour // 2410129
FIELD: medicine.SUBSTANCE: first hemodilution is performed by exfusion of undiluted autoblood. As volume-substituting component, applied is autoplasm, prepared by method of intermittent plasmapheresis at gestation term from 32 to 38 weeks. After achievement of surgical hemostasis reinfusion of prepared undiluted autoblood in amount 5-10 ml/kg of body weight is carried out. Method makes it possible to provide adequate compensation of operation blood loss by stabilisation of blood coagulation potential and restoration of erythrocyte population in blood stream.EFFECT: prevention of risk of developing complications in case of predicted blood loss in course of delivery due to following specific sequence of taken measures.3 tbl, 3 ex
 
2551233.
Up!